Filed with ASX · · 3 pages · English
Arovella Therapeutics Limited has reported the results of its Annual General Meeting, where nine out of ten resolutions were approved by poll. The filing includes details of the proxies received and votes cast for each resolution, in compliance with ASX Listing rules and the Corporations Act. Arovella Therapeutics is focused on developing its iNKT cell therapy platform for treating various cancers and autoimmune diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 4 November 2026 RESULTS OF ANNUAL GENERAL MEETING MELBOURNE, AUSTRALIA 4 November 2026: Arovella Therapeutics, (ASX: ALA), advises that nine out of ten resolutions considered at the Annual General Meeting held today were carried by...
Arovella Therapeutics Limited on 6ix
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics